That research was written in conjunction with the company and its what we have been waiting for with regards to strategic direction. The report gives some amazing insight.
I was unaware that EU and US trials can be merged!! 1 joint trial can be used as a pivotal study which can be used by both regulators. That sounds like a good plan and would reduce cost significantly.
Wow. Seem they are targeting the while muscular dystrophy space which adds 125,000 more potential patients on top of DMD.
Im strongly sticking with my FMG and greater than $5 call.
Excellent read.
ANP Price at posting:
14.0¢ Sentiment: Buy Disclosure: Held
